Abstract:A number of potential advantages, development of promising new agents, and the discovery of synergy with cytokines or cell products continue to spur research into the application of chemical immunomodulators for the treatment of cancer and AIDS. In preclinical in vitro and in vivo systems, chemical immunomodulators definitely modulate the immune system and have therapeutic efficacy. Although clinical trials have shown the ability of these agents to modulate the human immune system, thus far chemical immunomodulators have generally not fulfilled the therapeutic promise generated in animal models for the treatment of human diseases. While the discrepancy in results between animal models and human trials is obvious, the basis is not apparent. Species differences in elimination kinetics, presentation of active drug at the site of action, and the development of tachyphylaxis have been postulated as reasons for the minimal activity of these agents in humans. In addition, the use of investigational techniques established for cytotoxic agents may not be appropriate for immunomodulators. As with any immunomodulator, determining an optimal immunostimulatory dose and schedule and applying the therapy to patients with minimal tumor burden would perhaps be more appropriate than use of a maximally tolerated dose in patients with advanced disease. A dose-immunological effect relationship has recently been demonstrated for levamisole at doses higher than those used for many years in levamisole trials (99). While research and clinical investigation have identified several potentially useful chemical immunomodulators, the elementary understanding of the biochemical mechanisms involved in immunoregulation remains basic. Future research must elucidate these mechanisms, particularly in humans, to maximize the benefits of chemical immunomodulators as single agents or combined with cytotoxic chemotherapeutic agents, surgery, radiation therapy, other immunomodulators, and antiviral agents.

Approaches Towards Better Immunosuppressive Agents

Immunomodulation—a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system

Progress of immunosuppressant research

Recent Advances in Research of Immunosuppressive Drugs

Application of chemical immunomodulators to the treatment of cancer and AIDS.

Novel amides of mycophenolic acid and some heterocyclic derivatives as immunosuppressive agents

Genetically modified immunomodulatory cell-based biomaterials in tissue regeneration and engineering

Immune-enhancing agents in autoimmune skin diseases – A review

N-Arylated-Lactam-Type Iminosugars As New Immunosuppressive Agents: Discovery, Optimization, and Biological Evaluation

Progress in Contribution of Genetic Polymorphisms of the Related Genes to the Clinical Application of Immunosuppressive Drugs in Organ Transplantation

Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs

Glucocorticoids-based Prodrug Design: Current Strategies and Research Progress

Polysaccharide Immunomodulators as Therapeutic Agents: Structural Aspects and Biologic Function

The design, synthesis and in vitro immunosuppressive evaluation of novel isobenzofuran derivatives.

Immunosuppressive Cyclotides: A Promising Approach for Treating Autoimmune Diseases

Discovery of A New Class of Immunosuppressants from Trichothecium Roseum Co-Inspired by Cross-Kingdom Similarity in Innate Immunity and Pharmacophore Motif

Lessons to Learn From Low-Dose Cyclosporin-A: A New Approach for Unexpected Clinical Applications

Synthesis, molecular docking and biological evaluation of 1,3,4-oxadiazole derivatives as potential immunosuppressive agents.

Synthesis and Biological Evaluation of N-Arylated-Lactam-Type Iminosugars As Potential Immunosuppressive Agents

Research Progress in Pharmacogenomics of Immunosuppressants after Organ Transplantation

Synthesis and immunopharmacological analysis of selected derivatives of N,N'-bis-/3-aziridine/butanoylalkylenediamines and imides of 3-aziridinesuccinic acid. I.